A tumor vasculature–based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors
Mehdi Alilou(Case Western Reserve University), Anant Madabhushi(Emory University), Mohammadhadi Khorrami(Case Western Reserve University), Prateek Prasanna(Case Western Reserve University), Amit Gupta(University of Washington), Priya Velu(University of Pennsylvania), Pingfu Fu(Medical College of Wisconsin), Vamsidhar Velcheti(Cleveland Clinic), Kaustav Bera(University Hospitals of Cleveland), Vidya Sankar Viswanathan(Case Western Reserve University), Pradnya D. Patil(Cleveland Clinic)
Cited by 41
Related Papers
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Predicting cancer outcomes with radiomics and artificial intelligence in radiology
|Nature Reviews Clinical Oncology|2021|810
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|416